日本語 
Japan is getting older. This is creating a need for new healthcare technologies. These technologies do not just treat diseases. Also try to understand how our bodies change over time. GlycanAge and ExoEarth Corporation are working together to make this happen in Japan.
They want to make it possible for more people in Japan to get biological age testing. This testing looks at how old our bodies are, not just how many years we have lived. They also want to start a research program that looks at glycan biomarkers and exosome science. This could help Japan become a leader in longevity technology. It will bring together testing, research data, personalized health and artificial intelligence.
This is a deal for Japans technology industry. Longevity is not a healthcare issue it is also a technology challenge. Companies need to find ways to collect and understand biological data. This creates opportunities for people who develop intelligence, biotechnology companies, laboratories and digital health providers.
Why is biological age testing important?
It gives us a way to look at aging.
Our chronological age tells us how years we have lived.. Our biological age looks at the signals in our body that are associated with aging.
GlycanAge looks at the patterns of glycosylation on immunoglobulin G. This is associated with how our immune system is working and if we have chronic inflammation. The company has been doing research on glycans for over thirty years. They have looked at over 300,000 samples. Have written over 350 scientific papers.
People are paying attention to this technology because chronic inflammation and immune aging are areas of research. If we can turn these signals into data we can study how our lifestyle and environment affect our aging.
The collaboration with ExoEarth Corporation is important because it connects glycan measurements with research on exosomes and biological data. This adds another layer to the research. Could help us understand aging better. GlycanAge and ExoEarth Corporation are working together to advance our understanding of biological age testing and its importance, in Japan.
ExoEarth Brings a Longevity Perspective
ExoEarth is creating what it calls a Japan-based longevity ecosystem that combines exosome science, biological data, AI analysis, food innovation and longevity programs. The company says its goal is to build a platform for personalized improvement of health and wellbeing.
The company has already formed a partnership with GlycanAge in Japan. GlycanAge lists ExoEarth Corporation as a partner in the Asia-Pacific region, which gives the partnership a strong base for expanding access to biological age testing in the Japanese market.
This new strategic partnership could therefore take the relationship beyond testing and into research. Combining biological signals may eventually help researchers get a better understanding of how aging works.
However biological-age measurements should not be seen as a prediction of how long a person will live or as a replacement for medical diagnosis. The main benefit of these technologies is, in research, tracking and the overall understanding of health.
Impact on Japans Health-Tech Industry
The partnership can bring opportunities to Japans health-tech sector.
Japans health-tech sector will see opportunities because of this partnership.
As we do biological testing we need to make sure we have safe systems to collect and store health information. We also need to be able to analyze this information. This means companies will need cloud infrastructure AI analytics and data-security platforms. They will also need health applications.
AI will become very important as we get data. When we study how to live we have to look at a lot of things. These things include biomarkers, lifestyle, genetics and health records over time. Machine learning systems can help us find patterns that’re hard to see.
So Japanese technology companies that are good at AI, medical data and cloud computing can help make longevity platforms.
Opportunities for Research and Biotechnology Businesses
This partnership can also get technology companies, universities, laboratories and healthcare organizations to work more.
Japan is already good at biotechnology and medical science research. If we connect this expertise with platforms we can make new diagnostic technologies and research services faster.
ExoEarth is focused on exosome science, which’s very relevant. Exosomes are like messengers between cells. They can help us study diseases make diagnostics and regenerative medicine.
If we combine information, with glycan biomarkers we can give researchers more tools to study biological aging. However the real value will come from the results we get from this partnership not just from having more data.
Japans aging population is a deal.
Japan is a place for people who work on ways to help people live longer because the people in Japan are getting older really fast.
The country is having a lot of problems with taking care of people and making sure they have enough money. This is also a problem for the hospitals and the people who take care of the people. If we can find ways to help people stay healthy as they get older this could be very good for the economy.
For the people who own businesses it would be great to have ways to check on the health of their employees. This could help the employees stay healthy and not get sick much. For the insurance companies and the hospitals it would be great to have ways to know exactly what is going on with each persons body. This could help them give advice on how to stay healthy.
At the time businesses need to be careful, with peoples health information. They need to make sure they have permission to use this information and that they keep it safe. They also need to make sure that the information they are using is correct and based on science. If they can do this then the things they are working on to help people live longer could become very popular. Help a lot of people.
AI Could Become the Bridge Between Biology and Business
One of the most interesting aspects of the development is the convergence of biotechnology and AI.
ExoEarth explicitly identifies AI analysis as part of its broader longevity ecosystem. As more biological measurements become available, AI could help transform raw laboratory results into useful insights for researchers and individuals.
The opportunity for Japanese technology companies is to build the infrastructure surrounding those measurements rather than compete solely in the laboratory.
That could include AI-powered analytics, personalized dashboards, longitudinal health platforms and secure systems for integrating information from multiple biological tests.
A New Chapter for Japan’s Longevity Economy
The GlycanAge – ExoEarth collaboration reflects a broader shift in Japan’s technology industry toward preventive health, biological data and longevity technology.
Also Read: Kaigene Expands Drug Pipeline Through Taisho Deal
For biotechnology companies, it offers a route toward wider testing and research. For AI and software businesses, it creates demand for systems capable of interpreting increasingly complex biological information. For healthcare providers, it could eventually provide additional tools for understanding individual health trajectories.
The real impact will depend on continued scientific validation and responsible implementation. But the direction is clear: as Japan confronts the economic and social realities of population aging, technologies that help measure and understand healthy aging are likely to become increasingly important.
The partnership could therefore become part of a larger transformation in Japan’s health-tech industry—one where biotechnology, AI and data science work together to shift healthcare from simply responding to illness toward understanding health earlier and supporting healthier longevity.
English